G1 Therapeutics Acquisition and Executive Compensation Revamp

G1 Therapeutics (GTHX) has issued an announcement.

G1 Therapeutics, Inc. has struck a deal with Danish firm Pharmacosmos A/S to be acquired through a cash tender offer of $7.15 per share followed by a merger, subject to conditions including antitrust approvals. The transaction is designed for swift completion without a shareholder vote, leveraging Delaware corporate law. As part of the merger agreement, unvested stock options and certain equity incentives will be fully vested and converted to cash entitlements. G1’s leadership has approved the deal, deeming it beneficial for shareholders, while also amending executive employment agreements that enhance severance benefits post-merger. This strategic move is expected to reshape G1’s future operations and market presence.

Learn more about GTHX stock on TipRanks’ Stock Analysis page.